Reduced therapeutic effect w/ moderate P-gp or moderate CYP inducers (eg, oxcarbazepine, modafinil or efavirenz). Increased plasma conc w/ P-gp or BCRP inhibitors. Increased plasma conc of velpatasvir w/ OATP, CYP2B6, CYP2C8 or CYP3A4 inhibitors. Decreased solubility of velpatasvir w/ acid-reducing agents. Decreased C
max & AUC w/ famotidine, omeprazole, rifampicin, rifabutin. Decreased conc w/ carbamazepine, phenytoin, phenobarb & oxcarbazepine. Increase conc of rosuvastatin & statins. Velpatasvir: Increased C
max, AUC w/ digoxin; ketoconazole, itraconazole, voriconazole, posaconazole, isavuconazole; rosuvastatin, pravastatin. Decreased C
max, AUC w/ efavirenz, emtricitabine, tenofovir disoproxil fumarate.
Sign Out
